Publication in Scientific Reports

Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial Researchers in the group, in collaboration with colleagues from the Hormone Laboratory at Helse Bergen have published in Nature Scientific Reports

Published: (Updated: )

Figure fra Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS tria
The figure shows that changes in serum oestrogens are associated with plasma metabolite changes in postmenopausal metformin-treated women Photo: Nature Scientific reports

The study investigated how metformin affects breast tissue in postmenopausal breast cancer survivors with BMI > 25, aiming to understand its role in preventing the cancer recurring.

🔬 Methodology

  • A randomized, double-blind, placebo-controlled phase II trial (MetBreCS).
  • Analyzed transcriptomic, metabolomic, and steroid hormone profiles of breast tissue.

📉 Key Findings

  • Gene expression changes: Six genes (e.g., MS4A1, EGFL6) were differentially expressed in metformin-treated women.
  • Immune response: Down-regulation of immune-related genes linked to lower levels of arginine and citrulline.
  • Hormone metabolism: Altered expression of CYP11A1 and CYP1B1, suggesting changes in steroid hormone biosynthesis.

✅ Conclusion Metformin induces specific molecular changes in breast tissue that may help prevent new tumour development in postmenopausal women.